Aspirin and thrombinogenesis

Thrombosis Research

Volumn 110, Issue 5-6, 2003, Pages 345-347

  Szczeklik, A ^a   Musial J ^a   Undas, A ^a   Sanak, M ^a   Dropinski J ^a   Tuleja, E ^a   Wegrzyn W ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anticoagulant; Aspirin; Thrombinogenesis

Indexed keywords

ACETYLSALICYLIC ACID; BETA3 INTEGRIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5A; CHOLESTEROL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; LIPOPROTEIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTHROMBIN; ROFECOXIB; SIMVASTATIN; THROMBIN; THROMBOXANE A2;

ALLELE; AMINO ACID SUBSTITUTION; ANTICOAGULATION; BLEEDING TIME; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL ULTRASTRUCTURE; COMPLEX FORMATION; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MECHANISM; FIBRINOGEN METABOLISM; GENETIC ANALYSIS; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOGENESIS; THROMBOSIS;

EID: 0142258063     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.08.008     Document Type: Conference Paper

References (30)

1. Szczeklik A., Krzanowski M., Góra P., Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 80:1992;2006-2011.
2. MusiaŁ J., Radwan J., Szczeklik A. Aspirin delays thrombin generation in vitro through interaction with platelet phospholipids. Thromb. Res. 85:1997;367-368.
3. McKee S.A., Sane D.C., Deliargyris E.N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb. Haemost. 88:2002;711-715.
4. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L.et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88:2001;230-235.
5. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 105:2002;1650-1655.
6. Mazeaud M.M., Driss F., Le Quan Sang K.H., Duranthon V., Levenson J., Simon A.et al. Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients. Atherosclerosis. 94:1992;201-211.
7. Tremoli E., Colli S., Maderna P., Baldassarre D., Di Minno G. Hypercholesterolemia and platelets. Semin. Thromb. Hemost. 19:1993;115-121.
8. Davi G., Averna M., Catalano I., Barbagallo C., Ganci A., Notarbartolo A.et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 85:1992;1792-1798.
9. Rota S., McWilliam N.A., Baglin T.P., Byrne C.D. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin. Blood. 91:1998;508-515.
10. Szczeklik A., Musiał J., Undas A., Gajewski P., Góra P., Swadźba J.et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J. Am. Coll. Cardiol. 33:1999;1286-1293.
11. Musiał J., Undas A., Undas R., Brozek J., Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb. Haemost. 85:2001;221-225.
12. Undas A., Brummel K.E., Musiał J., Mann K.G., Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 103:2001;2248-2253.
13. Newman P.J., Derbes R.S., Aster R.H. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83:1989;1778-1781.
14. Weiss E.J., Bray P.F., Tayback M., Schulman S.P., Kickler T.S., Becker L.C.et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl. J. Med. 334:1996;1090-1094.
15. Zhu M.M., Weedon J., Clark L.T. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am. J. Cardiol. 86:2000;1000-1005.
16. Cooke G.E., Bray P.F., Hamlington J.D., Pham D.M., Goldschmidt-Clermont P.J. PlA2 polymorphism and efficacy of aspirin. Lancet. 351(25):1998;1253.
17. Andrioli G., Minuz P., Solero P., Pincelli S., Ortolani R., Lussignoli S.et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br. J. Haematol. 110:2000;911-918.
18. Szczeklik A., Undas A., Sanak M., Frołow M., Wȩgrzyn W. Relationship between bleeding time, aspirin, and the PIA1/A2 polymorphism of platelet glycoprotein IIIa. Br. J. Haematol. 110:2000;965-968.
19. Szczeklik A., Musiał J., Undas A. Reasons for resistance to aspirin in cardiovascular disease. Circulation. 106:2002;181e-182e.
20. Undas, Sanak M., Musiał J., Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet. 353:1999;982-983.
21. 3 integrins is associated with enhance thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 104:2001;2666-2672.
22. The CURE (Clopidogrel in Unstable Angina to prevent Recurrent Events) Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary without St- Segment elevation. N. Engl. J. Med. 34:2001;5494-5502.
23. Schneider D.J., Baumann P.Q., Holmes M.B., Taatjes D.J., Sobel B.E. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb. Haemost. 85:2001;309-313.
24. Furman M.I., Nurden P., Berndt M.C., Nurden A.T., Benoit S.E., Barnard M.R.et al. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb. Haemost. 84:2000;897-903.
25. Byzova T.V., Plow E.F. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J. Biol. Chem. 272:1997;27183-27188.
26. Byzova T.V., Plow E.F. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J. Cell Biol. 14:1998;2081-2092.
27. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B.et al. N. Engl. J. Med. 343:2000;1520-1528.
28. Tuleja E., Mejza F., Cmiel A., Szczeklik A. Effects of cyclooxygenases inhibitors on the balance of vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Atheroscler. Thromb. Vasc. Biol. 23:2003;1111-1115.
29. Solomon D.H., Glynn R.J., Levin R., Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 162:2002;1099-1104.
30. Rahme E., Pilote L., LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. 162(10):2002;1111-1115.